Legal & General Group
GNMX

Legal & General Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Legal & General Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,674
Closed -$15K – 3413
2017
Q1 		$15K Hold
7,674
– – ﹤0.01% 3146
2016
Q4 		$40K Buy
7,674
+3,114
+68% +$16.4K ﹤0.01% 2941
2016
Q3 		$24K Hold
4,560
– – ﹤0.01% 2786
2016
Q2 		$25K Buy
+4,560
New +$23.9K ﹤0.01% 2805
2014
Q4 		– Sell
-255,193
Closed -$1.33M – 2672
2014
Q3 		$1.33M Sell
255,193
-194,807
-43% -$1.26M ﹤0.01% 962
2014
Q2 		$3.56M Hold
450,000
– – ﹤0.01% 767
2014
Q1 		$3.06M Sell
450,000
-275,000
-38% -$2.15M ﹤0.01% 770
2013
Q4 		$4.29M Hold
725,000
– – 0.01% 712
2013
Q3 		$5.33M Hold
725,000
– – 0.01% 695
2013
Q2 		$2.83M Buy
+725,000
New +$2.97M ﹤0.01% 735

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Legal & General Group's GNMX Position: Q2 2017 in Review

Legal & General Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 7,674 shares — an estimated $15K sold.

Legal & General Group first reported a position in GNMX in Q2 2013 and held it in 10 quarters. The position peaked at $5.33M in Q3 2013. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Legal & General Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Legal & General Group sold 7,674 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $15K.
  • Legal & General Group first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 10 quarters.
  • Legal & General Group's Aevi Genomic Medicine Inc position peaked at $5.33M in Q3 2013.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Legal & General Group's 13F filing for Q2 2017, filed 3 Aug 2017.